Leerink Partnrs Has Bullish Outlook for LXRX Q4 Earnings

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Stock analysts at Leerink Partnrs raised their Q4 2024 EPS estimates for shares of Lexicon Pharmaceuticals in a research report issued to clients and investors on Thursday, November 14th. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.09). The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.69) per share. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ FY2025 earnings at ($0.50) EPS and FY2026 earnings at ($0.25) EPS.

LXRX has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Lexicon Pharmaceuticals in a research note on Wednesday, November 13th. Leerink Partners set a $6.00 price objective on shares of Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research report on Friday, October 18th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $6.00.

Lexicon Pharmaceuticals Stock Performance

NASDAQ:LXRX opened at $0.98 on Monday. Lexicon Pharmaceuticals has a twelve month low of $0.97 and a twelve month high of $3.73. The company has a quick ratio of 11.49, a current ratio of 7.45 and a debt-to-equity ratio of 0.56. The stock has a market cap of $240.13 million, a P/E ratio of -1.30 and a beta of 1.24. The business’s 50-day moving average price is $1.61 and its two-hundred day moving average price is $1.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The business had revenue of $1.75 million during the quarter, compared to analysts’ expectations of $3.14 million. During the same quarter last year, the business posted ($0.21) EPS.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in shares of Lexicon Pharmaceuticals by 8.4% during the 3rd quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company’s stock valued at $5,534,000 after purchasing an additional 273,436 shares during the last quarter. Barclays PLC boosted its position in Lexicon Pharmaceuticals by 391.6% during the third quarter. Barclays PLC now owns 193,873 shares of the biopharmaceutical company’s stock valued at $304,000 after buying an additional 154,436 shares during the period. XTX Topco Ltd purchased a new stake in Lexicon Pharmaceuticals during the third quarter valued at about $126,000. State Street Corp grew its stake in shares of Lexicon Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,471,215 shares of the biopharmaceutical company’s stock valued at $3,880,000 after buying an additional 157,738 shares during the last quarter. Finally, Atom Investors LP purchased a new position in shares of Lexicon Pharmaceuticals in the third quarter worth about $122,000. 74.70% of the stock is currently owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.